Hexaxim, a hexavalent combination vaccine for infants that was included in the National Immunization Program, may now be administered in general hospitals.

According to industry sources, Sanofi Korea's Hexaxim prefilled syringe has now passed the drug committees (DCs) of 17 medical institutions nationwide, including Seoul National University Hospital.

With its inclusion in Korea’s NIP (National Immunization Program), the number of medical institutions that offer Hexaxim vaccinations is expected to continue to increase.

As the first and only hexavalent combination vaccine in Korea (as of January 2025), Hexaxim can simultaneously protect against 6 infectious diseases, which